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ABSTRACT One of the mechanisms of cancer cell resistance toward chemotherapy is through cancer stem cells (CSCs),
which are characterized by excessive activation of regulator proteins such as human epidermal receptor 2 (HER2). Sappan
wood (Caesalpinia sappan L.) contains brazilin and brazilein that exhibit cytotoxic effects on several cancer cell lines. We
aimed to explore the potency of the ethanolic extract of sappan (EES) in CSCs through bioinformatic analyses and by using a
three‐dimensional (3D) breast cancer stem cells (BCSCs) for in vitro assay with two different models (i.e., BCSCs and HER2‐
BCSCs) in order to identify the potential therapeutic targets of genes (PTTGs). Bioinformatic analyses identified PTTGs,
which were further analyzed by gene ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment,
protein‐protein interaction (PPI) networks, and hub protein selection. Mammospheres were cultured under conditioned
media. The cytotoxic effects of EES were then measured by direct counting and based on the mammosphere‐forming
potential (MFP). Bioinformatic analysis disclosed PIK3CA and TP53 as PTTGs in BCSCs and HER2‐BCSCs, respectively.
In addition, the KEGG pathway analyses also demonstrated that PTTGs could regulate the ERBB pathway. EES thus
demonstrated cytotoxicity and inhibited the formation of mammospheres. Collectively, EES exhibited excellent potential
for further development as an inhibitor of cancer stem cells in breast cancer.
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1. Introduction
Cancer remains one of the diseases with the largest num­
bers of death associated with it owing to the abnormal­
ity of cell proliferation involved in this condition (Gar­
raway and Jänne 2012). Several approaches of estab­
lishing chemotherapeutic drugs targeted on several can­
cer pathways have been developed to treat such patients
(Cortés et al. 2014). The breakthrough of cancer treatment
has extensively changed over the past two decades, from
targeted cell proliferation to the use of specific markers on
cancer cells, which are generally less toxic (Kroschinsky
et al. 2017). Despite the fact that, relative to the situation
several years ago, the development of cellular resistance
to a specific treatment has been a significant concern con­
tributing to the failure of therapy in cancer (Garraway and
Jänne 2012).
One of the significant failures of cancer therapy is the
acquired chemoresistance of cancer cells. The adminis­
tration of a chemotherapy agent is conducted through re­
peated cycles. However, residual cancer cells remain a
small subset called as the cancer stem cells (CSCs) that
possess self­renewal and differentiation capabilities into
heterogeneous tumor cells, which are believed to affect
the recurrence of cancer cells (Koury et al. 2017). The
hallmarks of CSCs are marked with the cells’ capability to
inactivate drugs, alter targeted cells, and overexpress reg­
ulatory proteins such as the human epidermal receptor 2
(HER2) (Korkaya et al. 2008). The use of mammospheres
was the highlight of this study because it resembled the
body’s actual tumor. It also revealed the differences in
the cellular properties when compared to the usual two­
dimensional (2D) monolayer culture (Oak et al. 2012) and
increased the CSCs properties in mammospheres (Wang
et al. 2014).
Caesalpinia sappan L. or Sappan—a natural product
from Indonesia—has been known to profoundly inhibit tu­
mor growth in numerous cancer cells as well as in breast
cancer (Kim et al. 2005; Khamsita et al. 2012; Nurzijah
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et al. 2012; Rachmady et al. 2016; Rivanti et al. 2016;
Naik Bukke et al. 2018; Hanif et al. 2019; Meiyanto et al.
2019). Significantly, the anticancer activity from sappan
is mediated via several mechanisms: inhibiting the cell cy­
cle progression, triggering apoptosis, decreasing the re­
active oxygen species (ROS) level and senescence, in­
hibiting cancer cells’ migration by suppressing the matrix
metalloproteinase­9 (MMP­9) activity, and inhibiting the
HER2 expression (Khamsita et al. 2012; Haryanti et al.
2016; Rachmady et al. 2016; Hanif et al. 2019). Two
major compounds in C. sappan: brazilin and brazilein,
also demonstrated remarkable outcomes in inhibiting tu­
mor growth through the respective predictive mechanisms
mentioned above (Handayani et al. 2017; Jenie et al. 2018,
2020) and targets in several proteins responsible for can­
cer metastasis, includingMMP­9 via NF­κB, MMP­2, and
Rac1 proteins (Kim et al. 2012; Hsieh et al. 2013; Han­
dayani et al. 2016).
This study focused on examining the potency of the
ethanolic extract of sappan (EES) in breast cancer stem
cells (BCSCs) using 3D mammospheres from MCF­7 and
MCF­7/HER2 breast cancer cells. Moreover, integrated
bioinformatics was also utilized in predicting the potential
therapeutic target of genes (PTTGs) from EES in BCSCs
and HER2­BCSCs, thereby highlighting the relationship
between EES and inhibition in BCSCs. Our findings from
this study can be fundamental for the development of EES
as an alternative agent for the inhibition of CSCs on breast
cancer cells and overcoming chemotherapy resistance.
2. Materials and Methods
2.1. Protein‐protein interaction (PPI) network and hub
genes analysis
We analyzed seven compounds found in sappanwood (i.e.,
Butein, Sappanchalcone, Protosappanin A, Sappanone B,
Euxanthone, Brazilein, and Brazilin) (Cuong et al. 2012;
Nirmal et al. 2015) to discover the possible involvement
from EES in BCSCs. Direct protein targets (DTPs) of
each compound were collected from STITCH (Kuhn et al.
2014). Indirect protein targets (ITPs) were downloaded
from STRING­DB v11 with a confidence score of 0.7 and
no more than 20 interactions (Szklarczyk et al. 2015). The
regulatory genes of BCSCs and HER2­BCSCs regulatory
genes were collected from OMIM and PubMed, respec­
tively. All cumulative DTPs and ITPs were then called
potential therapeutics target genes (PTTGs). A Venn dia­
gram was prepared between the target genes of EES com­
pounds and BCSCs­regulatory genes and HER2­BCSCs
regulatory genes. The gene list was constructed for the
protein–protein interaction (PPI) network with STRING­
DB v11 (Szklarczyk et al. 2015), with confidence scores
>0.7 that were considered significant. Further analysis of
the PPI network was visualized by the Cytoscape (Shan­
non et al. 2003).
2.2. Gene ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway analysis
We utilized the GO andKEGG pathway enrichment analy­
sis were conducted as previously conducted by Hermawan
and Putri (2020) by using WebGestalt (WEB­based GEne
SeT AnaLysis Toolkit) with the Over­Representation En­
richment Analysis (ORA), p < 0.05 was used as the thresh­
old value (Wang et al. 2017).
2.3. Analysis of genetic alterations of the potential
therapeutics target genes (PTTGs)
The genetic alterations of the PTTGs were generated using
the cBioPortal (Cerami et al. 2012; Gao et al. 2013). The
breast cancer study with the top genetic alterations was se­
lected for subsequent connectivity analysis (p < 0.05 as the
cutoff value).
2.4. Sample preparation
The heartwood of sappan powder was obtained from the
Balai Besar Penelitian dan Pengembangan Tanaman Obat
dan Obat Tradisional (B2P2TOOT), Tawangmangu, In­
donesia, and was determined in the Faculty of Phar­
macy, Universitas Gadjah Mada. The extraction of heart­
wood was performed according to Meiyanto et al. (2019).
Briefly, 500 g of the powder was extracted through mac­
eration of 70% ethanol in 5 days, followed by evaporation
using a rotary vacuum evaporator to obtain EES. The ex­
traction process yielded 115 g of EES (23%). Later, the
extract was authenticated by thin­layer chromatography
(TLC) for Brazilein/Brazilin content.
2.5. Cell culture
MCF­7 breast cancer cells, both wild­type and transfected
with pcDNA5/TO­HER2 gene that overexpressed HER2
(MCF­7/HER2), were kindly provided by the Nara Insti­
tute of Science Technology, Japan. The cells were cul­
tured in DMEM high glucose (Gibco, Invitrogen, USA)
supplemented with 10% fetal bovine serum (FBS; Gibco),
1.5% penicillin­streptomycin (Gibco), and 0.5% Fungi­
zone (Gibco) at 37 °C under 5% CO2 incubator. Trypsin–
EDTA 0.25% (Gibco) was used to harvest the cells. The
cells were cultured in the PolyHEMA (Sigma, St. Louis,
CA, USA) coated tissue culture dish with conditioned
media to generate mammosphere. Dimethylsulfoxide
(DMSO; Merck, Germany) was added to dilute EES at a
105 μg/mL concentration.
2.6. Mammosphere generation and cytotoxicity
Mammosphere generation and cytotoxicity were per­
formed as previously described by Oak et al. (2012)
and Grimshaw et al. (2008). Briefly, the MCF­7 and
MCF­7/HER2 cells were seeded (4 × 104 cells/mL) in
PolyHEMA (50 mg/mL)­coated plate using conditioned
medium. The cells were allowed to grow and form mam­
mospheres for 3 days before the cytotoxic test. To perform
cytotoxicity, the prepared mammospheres were incubated
for the following 48 h with EES. At the end of the incuba­
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tion period, the mammospheres were observed by an in­
verted microscope and counted directly.
2.7. Mammosphere‐forming inhibition
The cells were pre­treated with EES for 24 h before seed­
ing (104 cells/well) in PolyHEMA (Sigma Aldrich, MO,
USA) coated 24­well plates and were further incubated for
72 h. At the end of the experiment, the mammosphere
was counted manually and presented as mammosphere­
forming potential (MFP), which was calculated as the
number of mammosphere per 10,000 cells (±SE) (Wang
et al. 2014).
2.8. Data analyses
For the cytotoxic assay, cell viability was calculated and
plotted into EES concentration versus cell viability (per­
cent of control) using theGraphPad Prism (GraphPad Soft­
ware, San Diego, California, USA). Mammosphere (MS)
formed (per 1 × 104 cells/well) was manually counted and
analyzed as MFP (MS per 1 × 104 cells).
3. Results and Discussion
3.1. The analysis of the PPI network of PTTGs of Cae‐
salpinia sappan L.
This study investigated the molecular target from the EES
in breast cancer using bioinformatics and in vitro ap­
proaches. A total of 687 genes was generated from 7 com­
pounds (Supplementary Table 1). We collected 1280 reg­
ulatory genes of BCSCs (Supplementary Table 2) and 171
HER2­BCSCs regulatory genes (Supplementary Table 3)
from OMIM and PubMed, respectively. We found out 146
and 56 genes were the target genes of EES compounds
in BCSCs­regulatory genes and HER2­BCSCs regulatory
genes, respectively (Supplementary Tables 4 and 5).
We then established all the genes into the PPI network
using STRING and visualized them using the Cytoscape.
The top genes related to BCSCs with the highest degree
score were recognized as EGFR, EGF, PIK3R1, TP53,
PIK3CA, AKT1, STAT3, VEGFA, MAPK1, and IL6 (Fig­
ure 1a), whereas KRAS, MYC, and CDH1 were present as
a part of PTTGs in HER2­BCSCs (Figure 1b). The differ­
ence between these results indicated the HER2­signaling
pathway alters the molecular mechanism in BCSCs.
3.2. GO analysis of PTTGs related to BCSCs and HER2‐
BCSCs
GOanalysis of PTTGswas classified into three groups: bi­
ological process, cellular component, and molecular func­
tion (Figure 2). Among the PTTGs in BCSCs and HER2­
BCSCs participated in the biological processes of response
stimulus, biological regulation, and metabolic process. In
addition, the PTTGs were located in the membrane, nu­
cleus, and cytosol, which play an essential role in the
molecular function in protein, ion, nucleic acid binding,
and enzyme regulator activities. KEGG enrichment in­
dicated several pathways regulated by PTTGs (Supple­
mentary Tables 6 and 7), such as cancer and the HER2­
signaling pathways. Several PTTGs were involved in
these signaling pathways, including KRAS, JUN, MMP9,
EGFR, MAPK1, and PI3KCA.
3.3. Genetic alterations among the hub proteins of
PTTGs
A total of 11 potential target genes of PTTGs were an­
alyzed using the cBioportal in order to explore their
genomic alterations across BCSCs and HER2­BCSCs.
AKT1, EGFR, PIK3CA, PIK3R1, MAPK1, KRAS, MYC,
and TP53 were selected from the highest degree score us­
ing the Cytoscape and KEGG pathway enrichment anal­
ysis, while MMP9 was selected from the KEGG pathway
analysis. The METABRIC studies (Lefebvre et al. 2016)
were selected for subsequent analyses. Genetic alterations
for each target genewere revealed in BCSCswith the high­
est percentage from PIK3CA (42%), followed by AKT1
(5%) and EGFR (4%) (Figure 3a). On the other hand, in
HER2­BCSCs, Oncoprint analyses revealed that genetic
alterations of PTTGs occurred in 4–42% of patients’ sam­
ples, dominated by p53 amplification, which is present as
the most common gene alteration (Figure 3b). This find­
ing indicated that the involvement of HER2 may change
the genetic alterations in BCSCs.
3.4. EES inhibits mammosphere formation and growth
in BCSCs and HER2‐BCSCs
We successfully generated mammospheres from MCF­
7/HER2with a density of 10,000 cells/well, using the same
procedure as previously mentioned. Mammospheres were
formed from the MCF­7/HER2 cells in 3–7 days (Figure
4a). Next, we treated the mammospheres with EES in or­
der to determine the cytotoxic effect on mammospheres by
the MTT assay. The treatment of EES for 48 h reduced the
mammospheres’ viability fromMCF­7 and MCF­7/HER2
(Figure 4b). Interestingly, the data itself demonstrated that
EES appeared more sensitive on the mammospheres from
MCF­7 than from MCF­7/HER2, as assessed by the low­
est tested concentration (10 μg/mL) caused a decrease of
viable cells up to 70% in BCSC. Simultaneously, it re­
quired a higher dose of EES to inhibit the mammosphere
growth in HER2­BCSCs. Our data also demonstrated
that the treatment using EES significantly (p < 0.001) in­
hibited mammospheres formation based on MFP (Figure
4c). These findings collectively highlighted the potential
of EES as a potential candidate for BCSCs and HER2­
BCSCs­targeted therapy.
3.5. Discussion
In this study, we aimed to determine the effect of the EES
in BCSCs and HER2­BCSCs through a bioinformatic ap­
proach and the in vitro assay. Integrated bioinformatics
analysis retrieved through STITCH and STRING resulted
from PTTGs of EES in BCSCs. Hub proteins included
EGFR, VEGFA, p53, STAT3, and PIK3CA in both BC­
SCs and HER2­BCSCs. These targets were a part of re­
ceptor tyrosine kinase (RTK) pathways associated with in­
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(a)
(b)
FIGURE 1 The PPI network of PTTGs (analyzed by STRING) and hub genes (analyzed by CytoScape) ofCaesalpinia sappan related to (a) BCSCs
and (b) HER2‐BCSCs.
creased breast cancer aggressiveness (Butti et al. 2018). It
is also knowledgeable that EGFR signaling was also re­
sponsible for the significant pathways including Ras­Raf­
MAPK, PI3K/Akt, JNK/STAT, and PLCγ, which affected
a plethora of biological functions (Masuda et al. 2012).
GO enrichment analysis demonstrated that PTTGs are in­
volved in the biological processes of response to the stim­
ulus (as defined as a change in the state or activity of a
cell in terms of movement, secretion, enzyme production,
and gene expression). The PTTGs were located in the
membrane, cytosol, and nucleus. Furthermore, the PTTGs
played a molecular function in protein binding, both in
BCSCs and HER2­BCSCs. The KEGG’s pathway based
on PTTGs revealed the ERBB­signaling pathway regula­
tion that also correlates with a prior analysis with STRING
(Figure 1). ERBB signaling plays a critical part in prolif­
eration, differentiation, survival, and migration (Arteaga
2011). Once this pathway was dysregulated, the cell pro­
liferation becomes uncontrollable and promotes cellular
malignancies. The two most widely studied proteins in
the ERBB family: ERBB1 (HER1 or EGFR) and ERBB2
(HER2), was profoundly known to lead to the progression
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(a)
(b)
FIGURE 2 GO enrichment analysis of PTTGs related to (a) BCSCs and (b) HER2‐BCSCs.
of cancer, which is also crucial to initiate metastasis, as
was notable in breast cancer (Hsu and Hung 2016). An­
other study by Hermawan and Putri (2020) explored the
target of brazilin (one of the major compounds in C. sap­
pan L.) in the TNBC metastatic breast cancer model re­
vealed that the inhibition of brazilin was possible through
blocking in the TNFα pathway. Different features partly
influence this distinct mechanism from TNBC with any
other subtypes (including ER+ and HER2+).
This study revealed that the generation of mammo­
spheres using polyHEMA­coated dish under conditioned
medium, which is themedium used for culturing cells from
splitting to achieve 80% confluency, was also interesting
and successfully utilized in prior studies by using agarose­
coating (Bashari et al. 2016, 2019). The medium for cell
growth into the mammospheres consisted of several com­
ponents, as described in Oak et al. (2012). The possible
reason why the waste medium transformed 2D cells into
3D cells is that the medium lacked the nutrients. Thus, the
cells were found to be in distress and differentiated to sur­
vive rather than multiply (Fadaka et al. 2017). Moreover,
the MCF­7 cells contained self­renewing mammosphere­
forming units (MFUs) (Piggott et al. 2011), and the exis­
tence of HER2 was also responsible for regulating cell dif­
ferentiation into mammospheres (Shah and Osipo 2016).
Treatment with EES exerts cytotoxicity that appeared
to be more sensitive in BCSCs than in HER2­BCSCs. Pre­
vious studies using 2D model cells by Khamsita et al.
(2012) and Rachmady et al. (2016) revealed that EES ex­
hibited a cytotoxic effect on theMCF­7 andMCF­7/HER2
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(a)
(b)
FIGURE 3 Summary alterations of hub genes among breast cancer studies and oncoprint of hub genes related to (a) BCSCs and (b) HER2‐
BCSCs.
cells with an IC50 value of 37 μg/mL and 25 μg/mL, re­
spectively. Unlike the prior studies, the treatment of EES
on the mammospheres took a longer time than the 2D
model, which is likely due to the mammospheres’ com­
plexity, which required more incubation time for EES to
inhibit mammospheres. According to the study by Konki­
malla et al. (2009) and (Hsieh et al. 2013), brazilein, one of
the major compounds in sappan, was proven to inactivate
NFĸB in the nucleus, causing the suppression of HER2.
The feasible explanation of the mechanism, in this case,
was the HER2 protein expression was not only associ­
ated with cell proliferation but also the CSCs progression,
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FIGURE 4 (a) Mammosphere formation from the MCF‐7 and MCF‐
7/HER2 cells under inverted microscope (magnification 400x); (b)
the cytotoxicity of EES on mammospheres from the MCF‐7 and
MCF‐7/HER2 cells; (c) EES inhibits mammosphere formation from
theMCF‐7 andMCF‐7/HER2 cells. The results represent the aver‐
age of three independent experiments (mean ±SD). Statistical anal‐
yses were conducted by using Student’s t‐test. ** or *** or ****
indicates p < 0.01 or p < 0.001 or 0.0001, respectively.
which affected the cell growth more aggressively (Ko­
rkaya et al. 2008; Oak et al. 2012; Shah and Osipo 2016).
Furthermore, the HER2 expression itself was regulated by
NFĸB (nuclear factor­kappa B). Simultaneously, HER2
could activate NFĸB, majorly via IKKα that was primarily
associated with the invasive phenotype in HER2­positive
breast cancer (Merkhofer et al. 2010). Nevertheless, the
NFkB activation resulted in increased mammosphere for­
mation in cell lines derived from theHER2­dependent can­
cer cells (Shah and Osipo 2016).
The current study serves as a limitation as it is interest­
ing to exert a physiological significance because, in vivo,
data was not present. However, we highlighted that EES
reduced the viability of BCSCs and HER2­BCSCs and
predicted the target with bioinformatics studies. There­
fore, a different approach needs to be explored to better
understand how EES inhibited CSCs formation, particu­
larly in the ERBB pathway. We believe that further evalu­
ation of EES using HER2 mutant through the in vitro and
in vivo assays should be interesting to elucidate the anti­
cancer effect from C. sappan. These findings eventually
added a new possible EES approach to act as an anticancer
agent targeted on BCSCs.
4. Conclusions
Through this study, we summarized that the EES exhib­
ited a cytotoxic effect and inhibited colony formation on
BCSCs and HER2­BCSCs. More importantly, the PTTGs
found responsible for the effects of EES in BCSCs and
HER2­BCSCs were EGFR, VEGFA, TP53, STAT3, and
PIK3CA. Furthermore, EES could possibly inhibit BCSCs
andHER2­BCSCs through the inhibition of the ERBB sig­
naling.
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